2025-03-09 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Review

**0. Key Figures Summary:**

* **Cumulative Return (VRTX):** 174.66%
* **Cumulative Return (VOO/S&P 500):** 108.62%
* **Return Difference:** 66.0%
* **Relative Outperformance:** 82.7% (relative to historical range)
* **Current Price:** $488.29
* **5-day Moving Average:** $487.04
* **20-day Moving Average:** $474.92
* **60-day Moving Average:** $447.81
* **RSI:** 74.16
* **PPO:** -0.03
* **Expected Long-Term Return (vs. S&P 500):** 13.3%


**1. Performance Comparison & Company Overview:**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines.  Over the period analyzed, VRTX significantly outperformed the S&P 500 (VOO), achieving a cumulative return of 174.66% compared to VOO's 108.62%.  The difference of 66.0% represents a substantial outperformance.  The relative outperformance of 82.7% indicates that this level of outperformance is relatively high compared to its historical performance against the S&P 500.

The provided Alpha and Beta analysis reveals a generally positive alpha (outperformance relative to the market) across the periods, except for 2019-2021. Beta values indicate varying levels of market sensitivity.  The company's market capitalization (Cap) has significantly increased over the years.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 48.0% | 21.7% | 19.0% | 0.1 | 38.5 |
| 2016-2018  | 66.0% | 11.0% | 47.0% | 0.1 | 42.5 |
| 2017-2019  | 88.0% | 11.0% | 57.0% | 0.6 | 56.2 |
| 2018-2020  | 17.0% | 22.8% | -10.0% | 0.2 | 60.7 |
| 2019-2021  | -9.0% | 22.8% | -80.0% | 0.2 | 56.4 |
| 2020-2022  | 10.0% | 22.8% | 2.0% | 0.2 | 74.2 |
| 2021-2023  | 84.0% | 9.6% | 60.0% | 0.5 | 104.5 |
| 2022-2024  | 64.0% | 13.7% | 31.0% | 0.5 | 103.4 |
| 2023-2025  | 66.0% | 13.7% | 17.0% | 0.5 | 125.4 |


**2. Recent Price Movement:**

VRTX's current price is $488.29, slightly above its 5-day moving average ($487.04) and significantly above its 20-day ($474.92) and 60-day ($447.81) moving averages. This suggests a recent upward trend.  The last day's price increased by 0.53%, indicating a mild upward movement.


**3. Technical Indicators & Expected Return:**

The RSI of 74.16 suggests the stock is approaching overbought territory, indicating potential short-term price correction. The negative PPO (-0.03) suggests bearish momentum, although this contradicts the upward price trend.  The 20-day relative divergence change of +6.8 points to short-term upward momentum. The large price change (0.53%) indicates a mild upward movement, not a sharp jump. A long-term investment (2+ years) is predicted to yield a 13.3% higher return compared to the S&P 500.


**4. Recent Earnings Analysis:**

| Date       | EPS      | Revenue    |
|------------|----------|------------|
| 2024-11-05 | 4.05     | $2.77 B    |
| 2024-08-02 | -13.92   | $2.65 B    |
| 2024-05-07 | 4.26     | $2.69 B    |
| 2023-11-07 | 4.01     | $2.48 B    |
| 2024-11-05 | 4.01     | $2.48 B    |  *(Duplicate Entry)*


Earnings show significant volatility.  The large negative EPS in Q2 2024 is a major concern and requires further investigation to understand the underlying reasons.  Revenue shows a generally upward trend. The duplicate entry for 2024-11-05 needs clarification.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.91B | 85.46% |
| 2024-09-30 | $2.77B | 85.84% |
| 2024-06-30 | $2.65B | 85.94% |
| 2024-03-31 | $2.69B | 87.27% |
| 2023-12-31 | $2.52B | 85.38% |


Revenue is increasing steadily. Profit margins remain consistently high, indicating strong profitability.

**Capital and Profitability:**

| Quarter | Equity | ROE     |
|---------|---------|---------|
| 2024-12-31 | $16.41B | 5.56%  |
| 2024-09-30 | $15.63B | 6.69%  |
| 2024-06-30 | $14.77B | -24.32% |
| 2024-03-31 | $18.55B | 5.93%  |
| 2023-12-31 | $17.58B | 5.51%  |


Equity shows some fluctuation. The extremely negative ROE in Q2 2024 (-24.32%) is a major concern and requires further investigation, possibly correlating to the negative EPS in the same quarter.


**6. Overall Analysis:**

VRTX has demonstrated strong historical outperformance against the S&P 500, with a significant cumulative return difference.  However, recent financial results show concerning volatility, particularly the substantial negative EPS and ROE in Q2 2024.  While the current price shows a positive short-term trend, the high RSI and negative PPO suggest caution.  Further investigation into the Q2 2024 results is crucial before making any investment decisions. The long-term outlook remains positive based on the expected return, but the short-term risks should be carefully considered.  The seemingly duplicate data entry should be clarified.
